Stem Cell Therapy in Cerebrovascular Disease

Michael I. Nahhas, David C Hess

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review: The purpose of this article is to provide a review of state-of-the-art cellular therapy in cerebrovascular diseases by discussing published and ongoing clinical trials. Recent findings: In spite of the challenge in translating the success of cellular therapy in acute strokes from preclinical models to clinical trials, early phase clinical trial have recently shown promise in overcoming these challenges. Various stem cell types and doses are being studied, different routes of administration are under investigation, as well as defining the optimal time window to intervene. In addition, experimental methods to enhance cellular therapy, such as ischemic preconditioning, are evolving. Summary: After the failure of neuroprotectants in cerebrovascular diseases, researchers have been keen to provide a way of replacement of damaged brain tissue and to promote recovery in order to achieve better outcomes. The field has progressed from intravenous delivery in the 24- to 36-h time window to later intracerebral administration in chronic stroke in clinical trials. New optimism in acute stroke care fostered by the success of mechanical thrombectomy will hopefully extend into cell therapy to promote recovery.

Original languageEnglish (US)
Article number49
JournalCurrent Treatment Options in Neurology
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Cerebrovascular Disorders
Cell- and Tissue-Based Therapy
Stem Cells
Clinical Trials
Stroke
Art Therapy
Ischemic Preconditioning
Thrombectomy
Neuroprotective Agents
Research Personnel
Brain
Therapeutics

Keywords

  • Cell therapy
  • Exosomes
  • Ischemic stroke
  • Stem cells

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Stem Cell Therapy in Cerebrovascular Disease. / Nahhas, Michael I.; Hess, David C.

In: Current Treatment Options in Neurology, Vol. 20, No. 11, 49, 01.11.2018.

Research output: Contribution to journalReview article

@article{d483c7f8b30e4b48bfba352b45c3d26a,
title = "Stem Cell Therapy in Cerebrovascular Disease",
abstract = "Purpose of review: The purpose of this article is to provide a review of state-of-the-art cellular therapy in cerebrovascular diseases by discussing published and ongoing clinical trials. Recent findings: In spite of the challenge in translating the success of cellular therapy in acute strokes from preclinical models to clinical trials, early phase clinical trial have recently shown promise in overcoming these challenges. Various stem cell types and doses are being studied, different routes of administration are under investigation, as well as defining the optimal time window to intervene. In addition, experimental methods to enhance cellular therapy, such as ischemic preconditioning, are evolving. Summary: After the failure of neuroprotectants in cerebrovascular diseases, researchers have been keen to provide a way of replacement of damaged brain tissue and to promote recovery in order to achieve better outcomes. The field has progressed from intravenous delivery in the 24- to 36-h time window to later intracerebral administration in chronic stroke in clinical trials. New optimism in acute stroke care fostered by the success of mechanical thrombectomy will hopefully extend into cell therapy to promote recovery.",
keywords = "Cell therapy, Exosomes, Ischemic stroke, Stem cells",
author = "Nahhas, {Michael I.} and Hess, {David C}",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s11940-018-0532-3",
language = "English (US)",
volume = "20",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "11",

}

TY - JOUR

T1 - Stem Cell Therapy in Cerebrovascular Disease

AU - Nahhas, Michael I.

AU - Hess, David C

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose of review: The purpose of this article is to provide a review of state-of-the-art cellular therapy in cerebrovascular diseases by discussing published and ongoing clinical trials. Recent findings: In spite of the challenge in translating the success of cellular therapy in acute strokes from preclinical models to clinical trials, early phase clinical trial have recently shown promise in overcoming these challenges. Various stem cell types and doses are being studied, different routes of administration are under investigation, as well as defining the optimal time window to intervene. In addition, experimental methods to enhance cellular therapy, such as ischemic preconditioning, are evolving. Summary: After the failure of neuroprotectants in cerebrovascular diseases, researchers have been keen to provide a way of replacement of damaged brain tissue and to promote recovery in order to achieve better outcomes. The field has progressed from intravenous delivery in the 24- to 36-h time window to later intracerebral administration in chronic stroke in clinical trials. New optimism in acute stroke care fostered by the success of mechanical thrombectomy will hopefully extend into cell therapy to promote recovery.

AB - Purpose of review: The purpose of this article is to provide a review of state-of-the-art cellular therapy in cerebrovascular diseases by discussing published and ongoing clinical trials. Recent findings: In spite of the challenge in translating the success of cellular therapy in acute strokes from preclinical models to clinical trials, early phase clinical trial have recently shown promise in overcoming these challenges. Various stem cell types and doses are being studied, different routes of administration are under investigation, as well as defining the optimal time window to intervene. In addition, experimental methods to enhance cellular therapy, such as ischemic preconditioning, are evolving. Summary: After the failure of neuroprotectants in cerebrovascular diseases, researchers have been keen to provide a way of replacement of damaged brain tissue and to promote recovery in order to achieve better outcomes. The field has progressed from intravenous delivery in the 24- to 36-h time window to later intracerebral administration in chronic stroke in clinical trials. New optimism in acute stroke care fostered by the success of mechanical thrombectomy will hopefully extend into cell therapy to promote recovery.

KW - Cell therapy

KW - Exosomes

KW - Ischemic stroke

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=85054861512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054861512&partnerID=8YFLogxK

U2 - 10.1007/s11940-018-0532-3

DO - 10.1007/s11940-018-0532-3

M3 - Review article

AN - SCOPUS:85054861512

VL - 20

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 11

M1 - 49

ER -